At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ETON Eton Pharmaceuticals, Inc.
Post-Mkt 10-30 17:39:25 EDT
52.18
-1.49
-2.78%
盘后53.94
+1.76+3.38%
17:36 EDT
High53.62Low51.89Vol335.70K
Open53.33D1 Closing53.67Amplitude3.22%
Mkt Cap1.49BTradable Cap1.16BTotal Shares28.58M
T/O17.60MT/O Rate1.51%Tradable Shares22.30M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Eton Pharmaceuticals, Inc. revenue is expected to increase by 89.82%, and institutional views are bullish
Earnings Agent  ·  10-30 01:44
Earning Preview: Eton Pharmaceuticals, Inc. revenue is expected to increase by 89.82%, and institutional views are bullish
Eton Pharmaceuticals to Report Third-Quarter Financial Results
Reuters  ·  10-29 18:54
Eton Pharmaceuticals to Report Third-Quarter Financial Results
US Stocks on the MOVE-Netflix, Coinbase Global, Accenture
Reuters  ·  10-15
US Stocks on the MOVE-Netflix, Coinbase Global, Accenture
Eton Pharmaceuticals Price Target Maintained with a $70.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-15
Eton Pharmaceuticals Price Target Maintained with a $70.00/Share by HC Wainwright & Co.
Eton Pharmaceuticals - Entered into Supply Agreement with Aquestive; Agreement for Libervant Has Initial Term of 20 Years - SEC Filing
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - Entered into Supply Agreement with Aquestive; Agreement for Libervant Has Initial Term of 20 Years - SEC Filing
Eton Pharmaceuticals - to Pay Aquestive Royalties at Mid-Teens Percentage Rate on Libervant Sales - SEC Filing
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - to Pay Aquestive Royalties at Mid-Teens Percentage Rate on Libervant Sales - SEC Filing
Eton Pharmaceuticals - to Pay Aquestive up to $47.50 Mln in Milestone Payments - SEC Filing
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - to Pay Aquestive up to $47.50 Mln in Milestone Payments - SEC Filing
Eton Pharmaceuticals - Under Agreement, Co Pays Aquestive Upfront License Fee of $10 Mln - SEC Filing
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - Under Agreement, Co Pays Aquestive Upfront License Fee of $10 Mln - SEC Filing
Eton Pharmaceuticals Licenses US Rights to Aquestive's Epilepsy Drug
MT Newswires Live  ·  10-14
Eton Pharmaceuticals Licenses US Rights to Aquestive's Epilepsy Drug
Eton and Aquestive announce license and supply agreement for Libervant
TIPRANKS  ·  10-14
Eton and Aquestive announce license and supply agreement for Libervant
Eton Pharmaceuticals - Libervant Commercial Launch Anticipated in April 2027, Subject to Final FDA Approval
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - Libervant Commercial Launch Anticipated in April 2027, Subject to Final FDA Approval
Eton Pharmaceuticals - Type 9 Nda Under FDA Review to Add Ages 6-11 to Libervant Label; Pdufa Date March 29, 2027
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - Type 9 Nda Under FDA Review to Add Ages 6-11 to Libervant Label; Pdufa Date March 29, 2027
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for Libervant® (Diazepam) Buccal Film
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for Libervant® (Diazepam) Buccal Film
Eton Pharmaceuticals - Libervant Has Orphan Drug Designation and Patent Protection Extending into 2038
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - Libervant Has Orphan Drug Designation and Patent Protection Extending into 2038
Eton Pharmaceuticals - Libervant Expected to be Eligible for Full Approval in Patients 12+ After Jan 10, 2027
THOMSON REUTERS  ·  10-14
Eton Pharmaceuticals - Libervant Expected to be Eligible for Full Approval in Patients 12+ After Jan 10, 2027
Is Impavido Launch Altering The Investment Case For Eton Pharmaceuticals (ETON)?
Simply Wall St.  ·  10-07
Is Impavido Launch Altering The Investment Case For Eton Pharmaceuticals (ETON)?
Eton Pharma Chief Business Officer David Krempa Sells 4,166 Common Shares for $229,405.56
Reuters  ·  10-07
Eton Pharma Chief Business Officer David Krempa Sells 4,166 Common Shares for $229,405.56
Eton Pharmaceuticals Down over 15%, on Pace for Largest Percent Decrease Since November 2023
Dow Jones  ·  10-01
Eton Pharmaceuticals Down over 15%, on Pace for Largest Percent Decrease Since November 2023
Eton Pharmaceuticals Launches Impavido Capsules to Treat Leishmaniasis
MT Newswires Live  ·  09-28
Eton Pharmaceuticals Launches Impavido Capsules to Treat Leishmaniasis
Eton Pharmaceuticals - Holds Exclusive Commercialization Rights for Impavido in the U.S.
THOMSON REUTERS  ·  09-28
Eton Pharmaceuticals - Holds Exclusive Commercialization Rights for Impavido in the U.S.

Introduction

Company Name.
Eton Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Issue price:
--